Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06) by Jae Ho Byun, Jeeyun Lee, Kyong Hwa Park, Eun Joo Kang, Sang Joon Shin, In Gyu Hwang, Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Jason K Sa, Sook Ryun Park, Jung Sun Kim, Yu Jung Kim, Woo Kyun Bae, Won Jin Chang, Eun-Ok Kim

“…Background Immune-modulating antibodies targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have demonstrated promising antitumor efficacy in various types of cancers, especially highly mutated ones. …”
Get full text

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma by Xiao-Hong Xie, Li-Qiang Wang, Yin-Yin Qin, Xin-Qing Lin, Zhan-Hong Xie, Ming Liu, Jie-Xia Zhang, Ming Ouyang, Jun Liu, Ying-Ying Gu, Shi-Yue Li, Cheng-Zhi Zhou

“…Five patients (5/7, 71.4%) received ICIs (programmed cell death protein 1 [PD1]/programmed cell death ligand 1 [PDL1] monoclonal antibody) as second- or higher-line treatments. …”
Get full text

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL... by Zhiyu Huang, Yanjun Xu, Wei Hong, Lei Gong, Kaiyan Chen, Jing Qin, Fajun Xie, Feng Wang, Xin Tian, Xiangrui Meng, Wenlei Feng, Lingyan Li, Baihui Zhang, Xiaoyan Kang, Yun Fan

“…BackgroundQL1604 is a humanized immunoglobulin G4 monoclonal antibody against programmed cell death protein 1. This first-in-human, open-label phase I study aimed to investigate the safety and tolerability and to identify the recommended doses of QL1604 for future studies. …”
Get full text

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10 by Mu-Yang Huang, Yu-Chi Chen, Wen-Yu Lyu, Xin-Yu He, Zi-Han Ye, Can-Yu Huang, Xin-Ling He, Xiuping Chen, Xiaobing Chen, Baoxian Zhang, Guoyin Kai, Xiaolei Zhang, Ting Li, Mingqing Huang, Jin-Jian Lu

“…Profiting from the sustained clinical improvement and prolonged patient survival, immune checkpoint blockade of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has emerged as a revolutionary cancer therapy approach. …”
Get full text

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells by Se‐Hoon Lee, Yeongmin Kim, Bu‐Nam Jeon, Gihyeon Kim, Jinyoung Sohn, Youngmin Yoon, Sujeong Kim, Yunjae Kim, Hyemin Kim, Hongui Cha, Na‐Eun Lee, Hyunsuk Yang, Joo‐Yeon Chung, A‐Reum Jeong, Yun Yeon Kim, Sang Gyun Kim, Yeonhee Seo, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Hansoo Park, Kyoung Wan Yoon

“…However, the ICI responses are only achieved in a subset of patients, and the underlying mechanisms of the limited response remain unclear. 160 patients with non‐small cell lung cancer treated with anti‐programmed cell death protein‐1 (anti‐PD‐1) or anti‐programmed death ligand‐1 (anti‐PD‐L1) are analyzed to understand the early determinants of response to ICI. …”
Get full text

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer by Luis M Montuenga, Roy S Herbst, Luis Paz-Ares, David L Rimm, Kurt A Schalper, Alfonso Calvo, Myrto K Moutafi, Ioannis A Vathiotis, Magdalena Molero, Sandra Martinez Morilla, Javier Baena, Niki Gavrielatou, Laura Castro-Labrador, Gorka Ruiz de Garibay, Vera Adradas, Daniel Orive, Karmele Valencia, S Ponce Aix, Jon Zugazagoitia

“…Background Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit from programmed cell death protein-1 (PD-1) axis blockade, and new biomarkers of response are needed. …”
Get full text

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients by Ruixuan Geng, Hui Tang, Tingting You, Xiuxiu Xu, Sijian Li, Zepeng Li, Yuan Liu, Wei Qiu, Na Zhou, Ningning Li, Yuping Ge, Fuping Guo, Yuhong Sun, Yingyi Wang, Taisheng Li, Chunmei Bai

“…BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors works by reactivating immune cells. …”
Get full text

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolum... by Daniela A. Bota, Daniela A. Bota, Daniela A. Bota, Thomas H. Taylor, Thomas H. Taylor, Naomi Lomeli, Xiao-Tang Kong, Xiao-Tang Kong, Xiao-Tang Kong, Beverly D. Fu, Beverly D. Fu, Axel H. Schönthal, Samuel Singer, Deborah T. Blumenthal, Frank M. Senecal, Helena Linardou, Evangelos Rokas, Dimitris G. Antoniou, Virgil E. J. C. Schijns, Thomas C. Chen, Thomas C. Chen, Thomas C. Chen, Joseph Elliot, Apostolos Stathopoulos, Apostolos Stathopoulos, Apostolos Stathopoulos, Apostolos Stathopoulos

“…SITOIGANAP is composed of both autologous and allogeneic tumor cells and lysates.MethodsTwenty-one patients with rGBM received SITOIGANAP on 28-day cycles in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), cyclophosphamide, bevacizumab, and an anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibody (either nivolumab or pembrolizumab).ResultsThe mPFS was 9.14 months, and the median overall survival (mOS) was 19.63 months from protocol entry. …”
Get full text

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia by Yueting Huang, Yueting Huang, Huijian Zheng, Huijian Zheng, Yuwen Zhu, Yuwen Zhu, Yan Hong, Yan Hong, Jie Zha, Jie Zha, Zhijuan Lin, Zhijuan Lin, Zhifeng Li, Zhifeng Li, Caiyan Wang, Caiyan Wang, Zhihong Fang, Zhihong Fang, Xingxing Yu, Xingxing Yu, Long Liu, Long Liu, Bing Xu, Bing Xu

“…IntroductionDespite accumulated evidence in T-cell exhaustion in acute myeloid leukemia (AML), the immunotherapeutic targeting exhausted T cells such as programmed cell death protein 1 (PD-1) blockade in AML failed to achieve satisfying efficacy. …”
Get full text

Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor by Maiken Mellergaard, Sarah Line Skovbakke, Stine Dam Jepsen, Nafsika Panagiotopoulou, Amalie Bøge Rud Hansen, Weihua Tian, Astrid Lund, Rikke Illum Høgh, Sofie Hedlund Møller, Romain Guérillot, Ashleigh S. Hayes, Lise Tornvig Erikstrup, Lars Andresen, Anton Y. Peleg, Anders Rhod Larsen, Timothy P. Stinear, Aase Handberg, Christian Erikstrup, Benjamin P. Howden, Steffen Goletz, Dorte Frees, Søren Skov

“…Cancer immunotherapy targeting programmed cell death protein 1 (PD-1) enhances T-cell activity and is emerging for the treatment of certain viral infections, while its potential against bacterial infections remains elusive. …”
Get full text

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors by Xiao‐Li Wei, Chao Ren, Feng‐Hua Wang, Yang Zhang, Hong‐Yun Zhao, Ben‐Yan Zou, Zhi‐Qiang Wang, Miao‐Zhen Qiu, Dong‐Sheng Zhang, Hui‐Yan Luo, Feng Wang, Sheng Yao, Rui‐Hua Xu

“…Abstract Background Several programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) antibodies have been approved for cancer treatment worldwide. …”
Get full text

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma by Hsueh-Chien Chiang, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, Shang-Hung Chen, Chiao-Hsiung Chuang, I-Chin Wu, Tzu-Chun Hong, Juei-Seng Wu, Meng-Zhi Han, Wei-Ting Chen, Chien-Ming Chiang, Kuan-Kai Hung, Hsin-Yu Kuo

“…This study compared the treatment efficacy of sorafenib versus lenvatinib in combination with programmed cell death protein-1 (PD-1) inhibitors in patients with uHCC in a clinical setting. …”
Get full text

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early... by Yan Wang, Ning Li, Jing Zhang, Ying Liu, Zhongqi Li, Nong Xu, Zhimin Ma, Yafei Zhang, Haiping Jiang, Xiongfei Yu, Mei Kong, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Yimin Lu, Kui Zhao, Ziran Li, Yisen Wang, Lisong Teng

“…However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. …”
Get full text

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. by Xavier Matias-Guiu, Ana Vivancos, Jordi Ponce, Ignacio Melero, Alena Gros, Josep María Piulats, Carlos E De Andrea, Maria Lozano-Rabella, Jara Palomero, August Vidal, Carla Panisello, Ricky Tirtakasuma, Judit Díaz-Gómez, Daniela Grases, Helena Pasamar, Laura Arregui, Eduard Dorca Duch, Esther Guerra Fernández

“…In addition, CD8+ and CD4+ TIL subpopulations were isolated based on the differential expression of programmed cell death protein-1 (PD-1) (negative, dim and high) and CD39 (positive or negative) by fluorescence activated cell sorting (FACS), expanded in vitro, and screened for autologous tumor recognition. …”
Get full text

Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment by Jingfang Lv, Zheng Jiang, Junhu Yuan, Meng Zhuang, Xu Guan, Hengchang Liu, Yefeng Yin, Yiming Ma, Zheng Liu, Hongying Wang, Xishan Wang

“…BackgroundProgrammed cell death protein 1 (PD-1) receptor has two ligands,programmed death-ligand 1 (PD-L1) and PD-L2. …”
Get full text

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial by Ze Zhang, Wenwen Zhang, Mingyi Chen, Hongguang Wang, Tao Wan, Bingyang Hu, Shichun Lu, Zhanbo Wang, Xiaochen Zhao, Yuezong Bai, Yafei Wang, Xuerui Li, Shiqing Chen, Feilong Zhao, Jinping Cai, Shuang Tong, Haowen Tang, Tianyu Jiao, Junfeng Li, Huiyi Ye, Fangzhou Wang, Junning Cao, Lantian Tian, Shouwang Cai, Minggen Hu

“…Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor response rate in both the first-line and second-line treatment of advanced HCC. …”
Get full text

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors by Alfred Zippelius, Petra Herzig, Pratiksha Gulati, Christian Klein, Marta Trüb, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Marina Natoli, Klas Hatje, Fabian Junker, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Lothar Tietze, Laura Codarri-Deak, Henry Kao

“…Similarly, little is known on the differential effects of dual, compared with single, checkpoint inhibition.Methods We here performed in-depth characterization, including multicolor flow cytometry, single cell RNA sequencing and multiplex supernatant analysis, using tumor single cell suspensions from patients with cancer treated ex vivo with novel bispecific antibodies targeting programmed cell death protein 1 (PD-1) and TIM-3 (PD1-TIM3), PD-1 and LAG-3 (PD1-LAG3), or with anti-PD-1.Results We identified patient samples which were responsive to PD1-TIM3, PD1-LAG3 or anti-PD-1 using an in vitro approach, validated by the analysis of 659 soluble proteins and enrichment for an anti-PD-1 responder signature. …”
Get full text

The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model by Thi-Anh-Thuy Tran, Thi-Anh-Thuy Tran, Young-Hee Kim, Ga-Eun Kim, Shin Jung, Shin Jung, In-Young Kim, In-Young Kim, Kyung-Sub Moon, Kyung-Sub Moon, Young-Jin Kim, Young-Jin Kim, Tae-Kyu Lee, Tae-Kyu Lee, Hyosuk Yun, Je-Jung Lee, Je-Jung Lee, Hyun-Ju Lee, Chul Won Lee, Tae-Young Jung, Tae-Young Jung, Tae-Young Jung

“…Moreover, the combination of adjuvants such as lenalidomide and anti-programmed cell death protein 1 (PD1) with a peptide vaccine showed potential vaccine effects in previous studies. …”
Get full text

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer by Daniele Fanale, Chiara Brando, Lidia Rita Corsini, Sofia Cutaia, Mariano Catello Di Donna, Ugo Randazzo, Clarissa Filorizzo, Chiara Lisanti, Luigi Magrin, Vittorio Gurrera, Raffaella Romano, Alessandra Dimino, Tancredi Didier Bazan Russo, Daniel Olive, Salvatore Vieni, Gianni Pantuso, Antonio Giordano, Vito Chiantera, Antonio Russo, Viviana Bazan, Juan Lucio Iovanna

“…Because several studies showed a close correlation between OC patient’s clinical outcome and expression of programmed cell death protein-1 or its ligand (PD-1/PD-L1), the aim of our study was to investigate if plasma levels of immunomodulatory proteins may predict prognosis of advanced HGSOC women. …”
Get full text

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations by Nicola Principe, Nicola Principe, Nicola Principe, Wayne J. Aston, Danika E. Hope, Caitlin M. Tilsed, Caitlin M. Tilsed, Caitlin M. Tilsed, Scott A. Fisher, Scott A. Fisher, Scott A. Fisher, Louis Boon, Ian M. Dick, Ian M. Dick, Wee Loong Chin, Wee Loong Chin, Wee Loong Chin, Alison M. McDonnell, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Richard A. Lake, Richard A. Lake, Richard A. Lake, Jonathan Chee, Jonathan Chee, Jonathan Chee, Willem Joost Lesterhuis, Willem Joost Lesterhuis, Willem Joost Lesterhuis, Willem Joost Lesterhuis

“…Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. …”
Get full text